 | |
| Clinical data | |
|---|---|
| Trade names | Anturan, Anturane, Apo-sulfinpyrazone |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a682339 |
| Routes of administration | By mouth intravenous |
| ATC code | |
| Pharmacokinetic data | |
| Protein binding | 98–99% |
| Metabolism | liver |
| Excretion | kidney |
| Identifiers | |
| |
| CAS Number |
|
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| ECHA InfoCard | 100.000.325 |
| Chemical and physical data | |
| Formula | C23H20N2O3S |
| Molar mass | 404.48 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Sulfinpyrazone is auricosuricmedication used to treatgout. It also sometimes is used to reduceplatelet aggregation by inhibitingdegranulation of platelets which reduces the release ofADP andthromboxane.
Like other uricosurics, sulfinpyrazone works by competitively inhibitinguric acid reabsorption in theproximal tubule of thekidney.
Sulfinpyrazone must not be used in persons withrenal impairment or a history of uric acid kidney stones.[1]
Trial have found that,Sulfinpyrazone taken in specific daily dose immediately following a patient having suffered from amyocardial infarction seem to drastically reduce the incidence of sudden death by as much as 43% and cardiac mortality by 32% in the 24 months following theirheart attack.[2]
| pyrazolones / pyrazolidines | |
|---|---|
| salicylates | |
| acetic acid derivatives and related substances | |
| oxicams | |
| propionic acid derivatives (profens) |
|
| n-arylanthranilic acids (fenamates) | |
| COX-2 inhibitors (coxibs) | |
| other | |
| NSAID combinations | |
Key:underline indicates initially developed first-in-class compound of specific group;#WHO-Essential Medicines;†withdrawn drugs;‡veterinary use. | |
 | Thisdrug article relating to themusculoskeletal system is astub. You can help Wikipedia byadding missing information. |
